Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.50 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2661538 | 0.87 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA7CHRNA5CHRM3 | |
| SCHEMBL6280909 | 0.79 | L3MBTL1 (0.40) | — | |
| SCHEMBL27578439 | 0.78 | CDC25B (0.42) | — | |
| SCHEMBL2643778 | 0.75 | GAA (0.54) | — | |
| SCHEMBL27482947 | 0.75 | GAA (0.47) | — | |
| SCHEMBL2662734 | 0.75 | HDAC2 (0.37) | — | |
| SCHEMBL2652076 | 0.74 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA7CHRNA5 | |
| SCHEMBL2653097 | 0.74 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNA5CHRM3 | |
| SCHEMBL2660166 | 0.73 | ALDH1A1 (0.40) | — | |
| SCHEMBL5780109 | 0.71 | ALDH1A1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194410-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH AS (DK) | 2006-01-18 | — | — | EP | disclosed |
| US-6936613-B2 | Benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | CHRNB2 961/4885CHRNA4 222/4885CHRNA7 260/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | CHRNB2 880/4885CHRNA4 230/4885CHRNA7 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.